Paul Lammers

Paul Lammers

Company: Triumvira Immunologics

Job title: President & CEO

Seminars:

Using the Natural TCR as a Strategy to Penetrate Solid Tumors 9:30 am

Demonstrate different structure and biology of TAC T cells compared to other T cell therapies Pursuit of TAC T cells in multiple solid tumor types Opportunity to develop TAC T cells as optimal Adoptive Cell TherapyRead more

day: Day Two

Panel Discussion: Exploring the Potential of Soluble TCR Therapies to Redirect and Activate T Cells 1:00 pm

How do we enhance receptor-target interactions to develop safe and efficacious soluble TCR products? Beyond survival benefit, how do we define the clinical response rate to determine success in phase 3 clinical trials? What are the lessons that we have taken from antibodies?Read more

day: Day Two

Panel Discussion: Optimizing Development of Combination Approaches to Overcome the Solid Tumor Microenvironment 10:30 am

Exploring how to train T cells to overcome immune defence and survive in the low-nutrient, acidic and hypoxic tumour microenvironment Utilizing anti-PD1 antibody fragments secreted from T-cells after tumor interaction to overcome the local suppressive environment Profiling metabolic TME immuno-suppressive mechanisms through use of novel technology platformsRead more

day: Day Two

Chairman’s Opening Remarks 9:25 am

Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.